In this article

LLY

Follow your favorite stocks CREATE FREE ACCOUNT

Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.

Shares of the company rose more than 3% on Thursday.

The pharmaceutical giant now expects its fiscal 2025 revenue to come in between $63 billion and $63.5 billion, up from a previous guidance of $60 to $62 billion. Eli Lilly also expects full-year adjusted profit to come in between $23 and $23.70 per share, up from its previous outlook of $21.75 to $23 a share.

Eli Lilly said the guidance reflects President Donald Trump 's existing tariffs as of Thursday, bu

See Full Page